DE60233576D1 - Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen - Google Patents
Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren VerwendungenInfo
- Publication number
- DE60233576D1 DE60233576D1 DE60233576T DE60233576T DE60233576D1 DE 60233576 D1 DE60233576 D1 DE 60233576D1 DE 60233576 T DE60233576 T DE 60233576T DE 60233576 T DE60233576 T DE 60233576T DE 60233576 D1 DE60233576 D1 DE 60233576D1
- Authority
- DE
- Germany
- Prior art keywords
- subject
- gamma delta
- regulating
- immune response
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 title 1
- 108010002350 Interleukin-2 Proteins 0.000 title 1
- 229940126530 T cell activator Drugs 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 3
- 230000001105 regulatory effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007124 immune defense Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02292963A EP1426052B1 (de) | 2002-12-02 | 2002-12-02 | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60233576D1 true DE60233576D1 (de) | 2009-10-15 |
Family
ID=32309486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60233576T Expired - Lifetime DE60233576D1 (de) | 2002-12-02 | 2002-12-02 | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen |
| DE60331583T Expired - Lifetime DE60331583D1 (de) | 2002-12-02 | 2003-12-02 | Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60331583T Expired - Lifetime DE60331583D1 (de) | 2002-12-02 | 2003-12-02 | Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060194755A1 (de) |
| EP (2) | EP1426052B1 (de) |
| JP (1) | JP2006510629A (de) |
| AT (2) | ATE441420T1 (de) |
| AU (1) | AU2003292492B2 (de) |
| CA (1) | CA2507011A1 (de) |
| DE (2) | DE60233576D1 (de) |
| WO (1) | WO2004050096A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2836483B1 (fr) * | 2002-02-22 | 2006-09-15 | Innate Pharma | Procedes de production de lymphocytes gamma delta t |
| US7767842B2 (en) * | 2002-12-02 | 2010-08-03 | Innate Pharma Sa | Class of γδ T cells activators and use thereof |
| US20100291118A1 (en) * | 2003-12-02 | 2010-11-18 | Innate Pharma | Class of Gamma Delta T Cells Activators and Use Thereof |
| US20070134273A1 (en) * | 2004-02-10 | 2007-06-14 | Francois Romagne | Composition and method for the treatment of carcinoma |
| CA2564562A1 (en) | 2004-04-26 | 2005-11-03 | Innate Pharma | Adjuvant composition and methods for its use |
| AU2005274649B2 (en) * | 2004-08-19 | 2010-09-09 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy |
| US20090208517A1 (en) * | 2004-08-19 | 2009-08-20 | Bernhard Moser | Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy |
| WO2006039721A2 (en) | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| WO2006067635A2 (en) * | 2004-12-20 | 2006-06-29 | Innate Pharma S.A. | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT |
| BRPI0608926A2 (pt) * | 2005-03-22 | 2010-11-03 | Innate Pharma | ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta |
| US8338173B2 (en) * | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| KR20080111070A (ko) | 2006-03-17 | 2008-12-22 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 비스포스포네이트 화합물 및 방법 |
| US20100144678A1 (en) * | 2007-04-09 | 2010-06-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treating bone cancer |
| US20100189681A1 (en) * | 2007-06-01 | 2010-07-29 | Innate Pharma S.A. | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer |
| WO2009131730A2 (en) | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| EP2123285A1 (de) | 2008-05-21 | 2009-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleosid-Phosphorantigene zur Verwendung in der VGAMMA9VDELTA2-T-Zellen-vermittelten Therapie |
| EP2324040B1 (de) | 2008-09-10 | 2014-01-01 | Innate Pharma | Neue polymorphe form von chdmapp, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält |
| WO2010049438A2 (en) * | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
| CA2828657A1 (en) | 2011-03-11 | 2012-09-20 | Assistance Publique - Hopitaux De Paris | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |
| ES2811624T3 (es) * | 2011-03-11 | 2021-03-12 | Hopitaux Paris Assist Publique | Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico |
| JP2016501013A (ja) * | 2012-11-08 | 2016-01-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδＴ細胞の無ＩＬ−２増殖を誘導するための方法 |
| CA2923314A1 (en) * | 2013-09-05 | 2015-03-12 | Sanford-Burnham Medical Research Institute | Modulation of .gamma..delta.t cells |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| EP4045635A4 (de) * | 2019-10-17 | 2023-10-25 | The University of Hong Kong | Verfahren zur herstellung von aus v-t-zellen abgeleiteten exosomen zur behandlung von mit epstein-barr-virus assoziierten karzinomen |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6896871B2 (en) * | 1998-04-02 | 2005-05-24 | Mbc Research, Inc. | Biphosphonate conjugates and methods of making and using the same |
| EP1090106A2 (de) * | 1998-06-30 | 2001-04-11 | The Brigham And Women's Hospital, Inc. | Alkylamine und ihre verläufer als spezifische modulatoren der menschlichen gamma-delta t-zellfunktion. |
| FR2782722B1 (fr) * | 1998-09-01 | 2001-01-12 | Inst Nat Sante Rech Med | Nouveaux composes phosphoepoxydes, procede de fabrication et applications |
| FR2782721B1 (fr) * | 1998-09-01 | 2000-11-03 | Inst Nat Sante Rech Med | Nouveaux composes phosphohalohydrines, procede de fabrication et applications |
| DE60024969T2 (de) * | 1999-01-21 | 2006-09-07 | Chugai Seiyaku K.K. | 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten |
| FR2791981B1 (fr) * | 1999-04-06 | 2001-07-20 | Inst Nat Sante Rech Med | Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications |
| SK16682001A3 (sk) * | 1999-05-21 | 2002-04-04 | Novartis Ag | Liečivo na liečenie angiogenézy |
| CN1533279A (zh) * | 2001-07-20 | 2004-09-29 | �����ɷ� | 用于活化γ/δT-细胞的有机磷化合物 |
| US20050042751A1 (en) * | 2001-10-31 | 2005-02-24 | Michel Goldman | Generation and use of new types of dendritic cells |
| FR2836483B1 (fr) * | 2002-02-22 | 2006-09-15 | Innate Pharma | Procedes de production de lymphocytes gamma delta t |
| US20070134273A1 (en) * | 2004-02-10 | 2007-06-14 | Francois Romagne | Composition and method for the treatment of carcinoma |
-
2002
- 2002-12-02 DE DE60233576T patent/DE60233576D1/de not_active Expired - Lifetime
- 2002-12-02 EP EP02292963A patent/EP1426052B1/de not_active Expired - Lifetime
- 2002-12-02 AT AT02292963T patent/ATE441420T1/de not_active IP Right Cessation
-
2003
- 2003-12-02 EP EP03768074A patent/EP1569656B1/de not_active Expired - Lifetime
- 2003-12-02 CA CA002507011A patent/CA2507011A1/en not_active Abandoned
- 2003-12-02 AU AU2003292492A patent/AU2003292492B2/en not_active Ceased
- 2003-12-02 US US10/537,394 patent/US20060194755A1/en not_active Abandoned
- 2003-12-02 WO PCT/IB2003/006375 patent/WO2004050096A2/en active Application Filing
- 2003-12-02 AT AT03768074T patent/ATE459360T1/de not_active IP Right Cessation
- 2003-12-02 DE DE60331583T patent/DE60331583D1/de not_active Expired - Lifetime
- 2003-12-02 JP JP2004556710A patent/JP2006510629A/ja active Pending
-
2010
- 2010-06-28 US US12/824,685 patent/US20100254940A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003292492A1 (en) | 2004-06-23 |
| JP2006510629A (ja) | 2006-03-30 |
| EP1426052A1 (de) | 2004-06-09 |
| EP1426052B1 (de) | 2009-09-02 |
| WO2004050096A3 (en) | 2004-09-16 |
| DE60331583D1 (de) | 2010-04-15 |
| EP1569656B1 (de) | 2010-03-03 |
| AU2003292492B2 (en) | 2008-10-23 |
| US20060194755A1 (en) | 2006-08-31 |
| ATE441420T1 (de) | 2009-09-15 |
| US20100254940A1 (en) | 2010-10-07 |
| WO2004050096A2 (en) | 2004-06-17 |
| CA2507011A1 (en) | 2004-06-17 |
| EP1569656A2 (de) | 2005-09-07 |
| ATE459360T1 (de) | 2010-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60233576D1 (de) | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen | |
| IL172700A (en) | Methods for making neutralizing and cross-activating antibodies against kir2dl and drugs that include them for use in assessing antibody toxicity | |
| SG151278A1 (en) | Oral and personal care compositions and methods | |
| MY155909A (en) | Oral care compositions and methods | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| ES2182850T3 (es) | Procedimientos y composiciones para la microencapsulacion de adyuvantes. | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| ATE365534T1 (de) | Kosmetische hautpflegezusammensetzungen | |
| HRP20040684A2 (hr) | Spojevi 2,4-pirimidindiamina i njihova upotreba | |
| IL119461A (en) | 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines | |
| ATE433996T1 (de) | Humane dr4-antikörper und deren anwendungen | |
| ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| GB0209891D0 (en) | Novel compounds | |
| ES2165878T3 (es) | Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central. | |
| WO2003088931A3 (en) | Polymeric odor absorption ingredients for personal care products | |
| SI2275413T1 (sl) | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema | |
| BR0315644A (pt) | Piperazinil e diazapanil benzamidas e benzotioamidas | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE405261T1 (de) | Verwendung von castanospermine derivaten in der behandlung von hepatitis c | |
| PL365246A1 (en) | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions | |
| ATE406884T1 (de) | Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits | |
| DK0631772T3 (da) | Retinoidholdig sammensætning | |
| EA200200808A1 (ru) | Модифицированные цитокины, предназначенные для применения в терапии рака | |
| AR043918A1 (es) | Reduccion del crecimiento del vello utilizando una composicion que contiene difluorometilornitina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |